Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8140360 | 1.00 | KCNJ1 (0.47) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| SCHEMBL5864571 | 1.00 | KCNJ1 (0.47) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| SCHEMBL9756598 | 1.00 | KCNJ1 (0.47) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| SCHEMBL26091219 | 1.00 | KCNJ1 (0.47) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| SCHEMBL26091221 | 1.00 | KCNJ1 (0.47) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| Hydrochloric Acid SCHEMBL5013957 | 0.99 | KCNJ1 (0.46) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| Hydrochloric Acid SCHEMBL5013954 | 0.99 | KCNJ1 (0.46) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| SCHEMBL2953111 | 0.93 | KCNJ1 (0.44) | KCNJ1KCNH2TBXA2RHRH3ADRB1 | |
| Acetic Acid SCHEMBL21489543 | 0.92 | TBXA2R (0.42) | KCNJ1KCNH2TBXA2RHRH3KMT2A | |
| Hydrochloric Acid SCHEMBL6013527 | 0.90 | KCNJ1 (0.41) | KCNJ1KCNH2TBXA2RHRH3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321495-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-10-24 | — | — | US | claimed |
| US-20180369428-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY- ACADEMIC COOPERATION FOUNDATION (KR) | 2018-12-27 | — | — | US | claimed |
| EP-3281643-A2 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | Kyungpook National University Industry-Academic Cooperation Foundation (KR) | 2018-02-14 | — | — | EP | claimed |
| US-20240139333-A1 | 2,6-DICHLOROPHENYL ESTER COMPOUNDS AND USE THEREOF | FUSION PHARMACEUTICALS INC (CA) | 2024-05-02 | — | — | US | disclosed |
| EP-4346787-A1 | 2,6-DICHLOROPHENYL ESTER COMPOUNDS AND USE THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023091689-A1 | COMBINED USE OF MCR1-DIRECTED RADIOTHERAPY AND IMMUNE CHECKPOINT INHIBITION IN THE TREATMENT OF MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-11576987-B2 | Compositions and methods of treating melanoma | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2022251612-A1 | 2,6-DICHLOROPHENYL ESTER COMPOUNDS AND USE THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-12-01 | — | — | WO | disclosed |
| WO-1995015335-A2 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995014493-A1 | THREE-STEP PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0628077-A1 | HUMANISED ANTIBODIES DIRECTED AGAINST A33 ANTIGEN | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-12-14 | — | — | EP | disclosed |
| WO-1994013805-A1 | HUMANISED ANTIBODIES DIRECTED AGAINST A33 ANTIGEN | CELLTECH LIMITED (GB) | 1994-06-23 | — | — | WO | disclosed |
| EP-0522007-A4 | A FONCTIONALIZED COMPLEXAND | US COMMERCE (US) | 1993-06-16 | — | — | EP | disclosed |
| WO-1993002652-A2 | MODIFIED HAPTENS USEFUL AS IMAGING AND THERAPEUTIC AGENTS | HYBRITECH INCORPORATED (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0522007-A1 | A FONCTIONALIZED COMPLEXAND | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1993-01-13 | — | — | EP | disclosed |
| WO-1991014458-A1 | A FONCTIONALIZED COMPLEXAND | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4923985-A | Process for synthesizing macrocyclic chelates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1990-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369428-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | TST, CTH, CBS | KCNJ1 1140/4885KCNH2 2631/4885TBXA2R 3568/4885 |
| US-11576987-B2 | Compositions and methods of treating melanoma | MC1R, TIE1, RB1 | KCNJ1 4841/4885KCNH2 4830/4885TBXA2R 2456/4885 |
| US-20240139333-A1 | 2,6-DICHLOROPHENYL ESTER COMPOUNDS AND USE THEREOF | DDT, GSTA2, CYP2D6 | KCNJ1 4855/4885KCNH2 4717/4885TBXA2R 678/4885 |
| US-20190321495-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, MKI67 | KCNJ1 4826/4885KCNH2 4815/4885TBXA2R 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.